Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Treatment of the antiphospholipid syndrome with direct oral anticoagulantsPosition statement of German societies.

Bauersachs R, Langer F, Kalka C, Konstantinides S, Klamroth R, Oldenburg J, Schellong S, Scholz U, Stücker M, Lindhoff-Last E.

Vasa. 2019 Nov;48(6):483-486. doi: 10.1024/0301-1526/a000815. Epub 2019 Aug 20.

PMID:
31621546
2.

Therapie des Antiphospholipid-Syndroms (APS) mit DOAKs.

Bauersachs R, Schellong S, Stücker M, Oldenburg J, Kalka C, Scholz U, Lindhoff-Last E.

Hamostaseologie. 2019 Aug;39(3):298-300. doi: 10.1055/s-0039-1694789. Epub 2019 Aug 12. German. No abstract available.

PMID:
31404932
3.

Evaluation of the sensitivity and specificity of a novel line immunoassay for the detection of criteria and non-criteria antiphospholipid antibodies in comparison to established ELISAs.

Thaler MA, Bietenbeck A, Steigerwald U, Büttner T, Schierack P, Lindhoff-Last E, Roggenbuck D, Luppa PB.

PLoS One. 2019 Jul 24;14(7):e0220033. doi: 10.1371/journal.pone.0220033. eCollection 2019.

4.

[Modern treatment of deep vein thrombosis and pulmonary embolism].

Renczes J, Lindhoff-Last E.

Internist (Berl). 2019 Jun;60(6):644-655. doi: 10.1007/s00108-019-0609-4. Review. German.

PMID:
31119310
5.

Thrombus Formation in Isolated Left Atrial Appendage After Multiple Atrial Fibrillation Ablations Despite Oral Anticoagulation Followed by Percutaneous Appendage Closure.

Chen S, Schmidt B, Bordignon S, Bologna F, Lindhoff-Last E, Chun KRJ.

JACC Clin Electrophysiol. 2019 Mar;5(3):398-400. doi: 10.1016/j.jacep.2018.10.003. No abstract available.

PMID:
30898245
6.

[Anticoagulation in patients with venous thromboembolism: What have been the most important changes within the last 10 years?]

Lucks J, Lindhoff-Last E.

MMW Fortschr Med. 2018 Nov;160(Suppl 3):44-49. doi: 10.1007/s15006-018-1121-9. Review. German. No abstract available.

PMID:
30421197
7.

Low incidence of heparin-induced skin lesions in orthopedic surgery patients with low-molecular-weight heparins.

Schindewolf M, Paulik M, Kroll H, Kaufmann R, Wolter M, Boehncke WH, Lindhoff-Last E, Recke A, Ludwig RJ.

Clin Exp Allergy. 2018 Aug;48(8):1016-1024. doi: 10.1111/cea.13159. Epub 2018 Jun 5.

PMID:
29683226
8.

Reply: Fondaparinux and Direct Oral Anticoagulants: Promising Anticoagulant for Management of Heparin-Induced Thrombocytopenia.

Schindewolf M, Banik N, Lindhoff-Last E.

J Am Coll Cardiol. 2018 Apr 17;71(15):1710-1712. doi: 10.1016/j.jacc.2018.02.026. No abstract available.

9.

International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.

Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I, Guillermo C, Kawai Y, Lindhoff-Last E, Kitchen S.

Thromb Haemost. 2018 Mar;118(3):437-450. doi: 10.1055/s-0038-1627480. Epub 2018 Feb 12.

PMID:
29433148
10.

Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.

Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J, Madlener K, Pötzsch B, Klamroth R, Hankowitz J, Banik N, Eberle S, Müller MM, Kropff S, Lindhoff-Last E.

J Am Coll Cardiol. 2017 Nov 28;70(21):2636-2648. doi: 10.1016/j.jacc.2017.09.1099.

11.

A Synovial Cyst Originating from the Hip Joint as a Rare Cause of Recurrent Femoral Vein Thrombosis: Case Report and Literature Review.

Keese M, Dahi F, Lindhoff-Last E.

Ann Vasc Surg. 2017 Aug;43:313.e13-313.e15. doi: 10.1016/j.avsg.2017.02.016. Epub 2017 May 4. Review.

PMID:
28479436
12.

Direct oral anticoagulants (DOAC) - Management of emergency situations. Rationale and design of the RADOA-Registry.

Lindhoff-Last E.

Hamostaseologie. 2017 Apr 6. doi: 10.5482/HAMO-16-11-0043. [Epub ahead of print]

PMID:
28386620
13.

Nadroparin carries a potentially high risk of inducing cutaneous delayed-type hypersensitivity responses.

Schindewolf M, Recke A, Zillikens D, Lindhoff-Last E, Ludwig RJ.

Contact Dermatitis. 2017 Jul;77(1):35-41. doi: 10.1111/cod.12764. Epub 2017 Mar 14.

PMID:
28294347
14.

Direct oral anticoagulants (DOAC) - Management of emergency situations.

Lindhoff-Last E.

Hamostaseologie. 2017;37(4):257-266. doi: 10.5482/HAMO-16-11-0043. Epub 2017 Dec 28. Review.

PMID:
29582928
15.

Update: Direct oral anticoagulants (DOAC) - their use and clinical management remain a challenge.

Lindhoff-Last E, Scharf RE.

Hamostaseologie. 2017;37(4):237. doi: 10.1055/s-0037-1619835. Epub 2017 Dec 28. No abstract available.

PMID:
29582924
16.

A multicenter study to assess the reproducibility of antiphospholipid antibody results produced by an automated system.

Devreese KM, Poncet A, Lindhoff-Last E, Musial J, de Moerloose P, Fontana P.

J Thromb Haemost. 2017 Jan;15(1):91-95. doi: 10.1111/jth.13560. Epub 2016 Dec 18.

17.

Evaluation of antiphospholipid antibody assays using latent class analysis to address the lack of a reference standard.

Thaler MA, Bietenbeck A, Yin MX, Steigerwald U, Holmes AB, Lindhoff-Last E, Luppa PB.

Clin Chem Lab Med. 2016 Dec 1;54(12):1929-1937. doi: 10.1515/cclm-2016-0116.

PMID:
27227709
18.

Risk of long-term anticoagulation under sustained severe arterial hypertension: A translational study comparing warfarin and the new oral anticoagulant apixaban.

Pfeilschifter W, Steinstraesser T, Paulus P, Zeiner PS, Bohmann F, Theisen A, Lindhoff-Last E, Penski C, Wagner M, Mittelbronn M, Foerch C.

J Cereb Blood Flow Metab. 2017 Mar;37(3):855-865. doi: 10.1177/0271678X16642443. Epub 2016 Jul 20.

19.

Antifactor Xa Activity for the Management of Anticoagulation during Cardiac Surgery.

Reyher C, Würfel C, Lindhoff-Last E, Meybohm P, Zacharowski K, Moritz A, Schindewolf M, Weber CF.

Thorac Cardiovasc Surg. 2016 Sep;64(6):494-500. doi: 10.1055/s-0035-1570035. Epub 2016 Jan 12.

PMID:
26757210
20.

Thrombophilia and risk of VTE recurrence according to the age at the time of first VTE manifestation.

Weingarz L, Schindewolf M, Schwonberg J, Hecking C, Wolf Z, Erbe M, Lindhoff-Last E, Linnemann B.

Vasa. 2015 Jul;44(4):313-23. doi: 10.1024/0301-1526/a000447.

PMID:
26314364
21.

Screening for lupus anticoagulants in patients treated with vitamin K antagonists.

Isert M, Miesbach W, Stoever G, Lindhoff-Last E, Linnemann B.

Int J Lab Hematol. 2015 Dec;37(6):758-65. doi: 10.1111/ijlh.12409. Epub 2015 Jul 30.

PMID:
26224222
22.

Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome.

Isert M, Miesbach W, Schüttfort G, Weil Y, Tirneci V, Kasper A, Weber A, Lindhoff-Last E, Herrmann E, Linnemann B.

Ann Hematol. 2015 Aug;94(8):1291-9. doi: 10.1007/s00277-015-2374-3. Epub 2015 Apr 10.

PMID:
25859986
23.

Refinement of the cutoff values of the HemosIL AcuStar assay for the detection of anticardiolipin and anti-beta2 glycoprotein-1 antibodies.

Fontana P, Poncet A, Lindhoff-Last E, de Moerloose P, Devreese KM.

J Thromb Haemost. 2014 Dec;12(12):2034-7. doi: 10.1111/jth.12732. Epub 2014 Oct 16.

24.

[Incidental finding of pathological coagulation parameters].

Luxembourg B, Lindhoff-Last E.

Internist (Berl). 2014 Oct;55(10):1139-48. doi: 10.1007/s00108-014-3490-1. Review. German.

PMID:
25190093
25.

Thrombosis of the inferior vena cava and malignant disease.

Kraft C, Schuettfort G, Weil Y, Tirneci V, Kasper A, Haberichter B, Schwonberg J, Schindewolf M, Lindhoff-Last E, Linnemann B.

Thromb Res. 2014 Sep;134(3):668-73. doi: 10.1016/j.thromres.2014.07.012. Epub 2014 Jul 18.

PMID:
25081831
26.

New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness.

Mani H, Lindhoff-Last E.

Drug Des Devel Ther. 2014 Jun 17;8:789-98. doi: 10.2147/DDDT.S45644. eCollection 2014. Review.

27.

Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study.

Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J, Madlener K, Pötzsch B, Klamroth R, Hankowitz J, Banik N, Eberle S, Kropff S, Müller MM, Lindhoff-Last E.

Thromb Res. 2014 Jul;134(1):29-35. doi: 10.1016/j.thromres.2014.03.029. Epub 2014 Mar 18.

PMID:
24703295
28.

Prevalence of established risk factors for venous thromboembolism according to age.

Linnemann B, Weingarz L, Schindewolf M, Schwonberg J, Weber A, Herrmann E, Lindhoff-Last E.

J Vasc Surg Venous Lymphat Disord. 2014 Apr;2(2):131-9. doi: 10.1016/j.jvsv.2013.09.006. Epub 2014 Jan 16.

PMID:
26993177
29.

Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.

Mani H, Herth N, Kasper A, Wendt T, Schuettfort G, Weil Y, Pfeilschifter W, Linnemann B, Herrmann E, Lindhoff-Last E.

Ther Drug Monit. 2014 Oct;36(5):624-31. doi: 10.1097/FTD.0000000000000064.

PMID:
24577124
30.

Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAISTHRO registry.

Weingarz L, Schwonberg J, Schindewolf M, Hecking C, Wolf Z, Erbe M, Weber A, Lindhoff-Last E, Linnemann B.

Br J Haematol. 2013 Dec;163(5):655-65. doi: 10.1111/bjh.12575. Epub 2013 Oct 8.

PMID:
24219332
31.

Impact of the type of SERPINC1 mutation and subtype of antithrombin deficiency on the thrombotic phenotype in hereditary antithrombin deficiency.

Luxembourg B, Pavlova A, Geisen C, Spannagl M, Bergmann F, Krause M, Alesci S, Seifried E, Lindhoff-Last E.

Thromb Haemost. 2014 Feb;111(2):249-57. doi: 10.1160/TH13-05-0402. Epub 2013 Nov 7.

PMID:
24196373
32.

Main considerable factors for correct laboratory test interpretation under DOA treatment.

Mani H, Lindhoff-Last E.

Thromb J. 2013 Nov 1;11(1):22. doi: 10.1186/1477-9560-11-22.

33.

[Monitoring of coagulation during treatment with direct oral anticoagulants].

Kasper A, Lindhoff-Last E.

Dtsch Med Wochenschr. 2013 Oct;138(40):1997-2000. doi: 10.1055/s-0033-1349526. Epub 2013 Sep 24. German. No abstract available.

PMID:
24065404
34.

The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.

Pfeilschifter W, Luger S, Brunkhorst R, Lindhoff-Last E, Foerch C.

Cerebrovasc Dis. 2013;36(2):115-9. doi: 10.1159/000352062. Epub 2013 Sep 11.

PMID:
24029592
35.

Patients with inferior vena cava thrombosis frequently present with lower back pain and bilateral lower-extremity deep vein thrombosis.

Kraft C, Hecking C, Schwonberg J, Schindewolf M, Lindhoff-Last E, Linnemann B.

Vasa. 2013 Jul;42(4):275-83. doi: 10.1024/0301-1526/a000288.

PMID:
23823859
36.

Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays.

Lindhoff-Last E, Ansell J, Spiro T, Samama MM.

Ann Med. 2013 Sep;45(5-6):423-9. doi: 10.3109/07853890.2013.801274. Epub 2013 Jun 7. Review.

PMID:
23746003
37.

High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy.

Schindewolf M, Gobst C, Kroll H, Recke A, Louwen F, Wolter M, Kaufmann R, Boehncke WH, Lindhoff-Last E, Ludwig RJ.

J Allergy Clin Immunol. 2013 Jul;132(1):131-9. doi: 10.1016/j.jaci.2013.02.047. Epub 2013 May 30.

PMID:
23726261
38.

[Management of catheter-related upper extremity deep vein thrombosis].

Linnemann B, Lindhoff-Last E.

Zentralbl Chir. 2013 Dec;138 Suppl 2:e86-94. doi: 10.1055/s-0032-1328098. Epub 2013 Apr 10. Review. German.

PMID:
23575524
39.

Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations.

Mani H, Kasper A, Lindhoff-Last E.

J Thromb Thrombolysis. 2013 Aug;36(2):187-94. doi: 10.1007/s11239-013-0907-y. Review.

PMID:
23512159
40.

[Lower extremity deep vein thrombosis - diagnostic algorithm].

Linnemann B, Lindhoff-Last E.

Dtsch Med Wochenschr. 2013 Feb;138(8):369-74. doi: 10.1055/s-0032-1332903. Epub 2013 Feb 12. German. No abstract available.

PMID:
23404325
41.

Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.

Mani H, Hesse C, Stratmann G, Lindhoff-Last E.

Thromb Haemost. 2013 Jan;109(1):127-36. doi: 10.1160/TH12-04-0228. Epub 2012 Nov 8.

PMID:
23138190
42.

[Dabigatran therapy--perioperative management and interpretation of coagulation tests].

Spannagl M, Bauersachs R, Debus ES, Gawaz M, Gerlach H, Haas S, Hach-Wunderle V, Lindhoff-Last E, Riess H, Schellong S, Schinzel H, Bode C.

Hamostaseologie. 2012;32(4):294-305. doi: 10.5482/ha-2012030004. German.

PMID:
23114798
43.

[Risk of bleeding and haemorrhagic complication with rivaroxaban--periprocedural management of haemostasis].

Koscielny J, Beyer-Westendorf J, von Heymann C, Braun J, Klamroth R, Lindhoff-Last E, Tiede A, Spannagl M.

Hamostaseologie. 2012;32(4):287-93. doi: 10.5482/ha-2012030001. German.

PMID:
23114797
44.

Risk factors, management and primary prevention of thrombotic complications related to the use of central venous catheters.

Linnemann B, Lindhoff-Last E.

Vasa. 2012 Sep;41(5):319-32. doi: 10.1024/0301-1526/a000217. Review.

PMID:
22915529
45.

No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke.

Bohmann F, Mirceska A, Pfeilschifter J, Lindhoff-Last E, Steinmetz H, Foerch C, Pfeilschifter W.

PLoS One. 2012;7(7):e40804. doi: 10.1371/journal.pone.0040804. Epub 2012 Jul 24.

46.

Heparin-induced skin lesions.

Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH.

Lancet. 2012 Nov 24;380(9856):1867-79. doi: 10.1016/S0140-6736(12)60409-7. Epub 2012 May 28. Review.

PMID:
22642893
47.

Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.

Mani H, Rohde G, Stratmann G, Hesse C, Herth N, Schwers S, Perzborn E, Lindhoff-Last E.

Thromb Haemost. 2012 Jul;108(1):191-8. doi: 10.1160/TH11-12-0832. Epub 2012 Apr 26.

PMID:
22534775
48.

Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke.

Pfeilschifter W, Bohmann F, Baumgarten P, Mittelbronn M, Pfeilschifter J, Lindhoff-Last E, Steinmetz H, Foerch C.

Ann Neurol. 2012 May;71(5):624-33. doi: 10.1002/ana.23558. Epub 2012 Mar 23.

PMID:
22447744
49.

Performance of five D-dimer assays for the exclusion of symptomatic distal leg vein thrombosis.

Luxembourg B, Schwonberg J, Hecking C, Schindewolf M, Zgouras D, Lehmeyer S, Lindhoff-Last E.

Thromb Haemost. 2012 Feb;107(2):369-78. doi: 10.1160/TH11-07-0511. Epub 2012 Jan 11.

PMID:
22234425
50.

[JAK2 mutation and thrombosis - recommendations for screening].

Linnemann B, Lindhoff-Last E.

Dtsch Med Wochenschr. 2011 Dec;136(48):2454-7. doi: 10.1055/s-0031-1297265. Epub 2011 Nov 22. German. No abstract available.

PMID:
22109574

Supplemental Content

Loading ...
Support Center